Washington, D.C. 20549

Date of Report (Date of earliest event reported): February 8, 2024

(Exact name of registrant as specified in its charter)
Delaware 001-36352 20-8756903
(State or other jurisdiction
of incorporation)
File Number)
 (IRS Employer
Identification No.)
245 First Street
Cambridge, Massachusetts
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 871-2098
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading
 Name of each exchange
on which registered
Common Stock, par value $0.00001 per share AKBA 
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
        Compensatory Arrangements of Certain Officers.

As previously disclosed, on May 5, 2022, Akebia Therapeutics, Inc. (the “Company”) entered into a retention and separation agreement with each of Michel Dahan, the Company’s Chief Operating Officer, and Nicole R. Hadas, the Company’s Senior Vice President, Chief Legal Officer and Secretary. Pursuant to the retention and separation agreements as subsequently amended, Mr. Dahan would separate from the Company effective as of March 22, 2024 and Ms. Hadas would separate from the Company effective as of March 29, 2024, or, in the event of certain specified events, the effective date of their separation would extend to September 22, 2024.

On February 8, 2024, the Company and Mr. Dahan agreed to further extend the effective date of his separation to June 28, 2024 (the “Dahan February 2024 Amendment”).

On February 8, 2024, the Company and Ms. Hadas agreed to further extend the effective date of her separation to June 14, 2024 (the “Hadas February 2024 Amendment”).

The foregoing description of the amendments does not purport to be complete and are qualified in their entirety by reference to the Dahan February 2024 Amendment and the Hadas February 2024 Amendment, copies of which the Company expects to file as exhibits to its Annual Report on Form 10-K for the year ended December 31, 2023.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 13, 2024
By: /s/ John P. Butler
Name: John P. Butler
Title: President and Chief Executive Officer

Jan. 08, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 08, 2024
Entity Registrant Name AKEBIA THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36352
Entity Tax Identification Number 20-8756903
Entity Address, Address Line One 245 First Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 871-2098
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol AKBA
Entity Emerging Growth Company false
Entity Central Index Key 0001517022
Amendment Flag false
Entity Listings [Line Items]  
Security Exchange Name NASDAQ

Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Akebia Therapeutics Charts.
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Akebia Therapeutics Charts.